{"id":"W4382807727","doi":"10.1016/j.annonc.2023.04.087","title":"P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medac; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Ipsen; Servier; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; National Center for Global Health and Medicine; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; MacroGenics; Sanofi; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Response Evaluation Criteria in Solid Tumors; T cell; Chemotherapy; Clinical trial; Internal medicine; Oncology; Immunotherapy; Phases of clinical research; Cancer research; Pharmacology; Cancer; Immunology; Immune system; CD34; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00134614,0.0009970906,0.001294195,0.0003152042,0.0003669852,0.0008521342,0.0006129523,0.0009484112,0.004122296],"category_scores_gemma":[0.0008670639,0.0003354478,0.0009221503,0.0002847899,0.001108989,0.00079251,0.0004024079,0.003301815,0.0009906254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007548458,"about_ca_system_score_gemma":0.001545188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001012144,"about_ca_topic_score_gemma":0.002320184,"domain_scores_codex":[0.9996465,0.0001797088,0.00001346507,0.00005712437,0.00002435541,0.00007885246],"domain_scores_gemma":[0.999458,0.0001353368,0.00007375122,0.00006100329,0.00002126871,0.0002505195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.759367,0.0319639,0.004506564,0.001085583,0.001417975,0.0006444635,0.0003116814,0.007174127,0.05041942,0.001138078,0.008135051,0.1338361],"study_design_scores_gemma":[0.5880854,0.3879999,0.007928399,0.00006272583,0.0004795564,0.0006563879,0.00008688469,0.002592172,0.006734813,0.001065749,0.004271438,0.00003663824],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909295,0.001909444,0.0004641083,0.0006856656,0.0001346309,0.001652644,0.001037165,0.00009756036,0.003089145],"genre_scores_gemma":[0.9892452,0.00159528,0.001030244,0.0007124126,0.0001077141,0.001466541,0.002125357,0.00003163198,0.003685686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004122296,"threshold_uncertainty_score":0.01379043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1654089244587433,"score_gpt":0.4750678984302584,"score_spread":0.309658973971515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}